Scientists in Germany say they've made a nasal vaccine that can shut down Covid-19 infections before the virus takes hold. The vaccine is made with a live but weakened form of the coronavirus, which closely mimics the natural process of infection.
In hamster studies, two doses of the vaccine proved to be highly effective, blocking the virus from copying itself in the animals' upper airways and achieving "sterilizing immunity" โ preventing illness. This approach is promising, as it aims to boost mucosal immunity by boosting immune defenses in the tissues that line the upper airways.
The nasal vaccine was tested on hamsters infected with the original strain of Covid-19, but not Omicron. While it performed well against the original strain, its ability to neutralize Omicron was reduced. The researchers are now working on an update for the vaccine to tackle the new variant.
Other nasal vaccines are already in use or nearing completion in clinical trials. These include those from China and India, which rely on harmless adenoviruses to ferry their instructions into cells. However, effectiveness data for these vaccines has not been published yet.
The US is experiencing a "stalemate" with Covid-19, with hundreds of Americans still dying daily despite the pandemic's dark days being behind them. The virus continues to spread among people and animals, posing a danger to vulnerable groups such as the elderly and immunocompromised.
Researchers hope that next-generation Covid-19 vaccines could make the respiratory infection less of a threat by boosting mucosal immunity. These vaccines aim to shut down the virus before it makes us sick, ultimately preventing its spread.
One scientist, Emanuel Wyler, describes the nasal vaccine's approach as "bit like stationing firefighters underneath the smoke alarm in your house." The vaccine works by mimicking the natural process of infection and boosting immune defenses in the upper airways.
However, experts caution that more testing is needed before this vaccine can be widely used. Dr. Greg Poland from the Mayo Clinic notes that while the results are promising, there's still much to be done โ including repetition of the study in primates and humans.
In fact, there are already at least four nasal vaccines for Covid-19 in late-stage testing in people, according to the World Health Organization's vaccine tracker. These include those from Codagenix, which uses a live but weakened version of the virus similar to the German-developed vaccine.
While some experts see this approach as promising, others have concerns about its effectiveness and safety, particularly for vulnerable populations like those with compromised immunity.
In hamster studies, two doses of the vaccine proved to be highly effective, blocking the virus from copying itself in the animals' upper airways and achieving "sterilizing immunity" โ preventing illness. This approach is promising, as it aims to boost mucosal immunity by boosting immune defenses in the tissues that line the upper airways.
The nasal vaccine was tested on hamsters infected with the original strain of Covid-19, but not Omicron. While it performed well against the original strain, its ability to neutralize Omicron was reduced. The researchers are now working on an update for the vaccine to tackle the new variant.
Other nasal vaccines are already in use or nearing completion in clinical trials. These include those from China and India, which rely on harmless adenoviruses to ferry their instructions into cells. However, effectiveness data for these vaccines has not been published yet.
The US is experiencing a "stalemate" with Covid-19, with hundreds of Americans still dying daily despite the pandemic's dark days being behind them. The virus continues to spread among people and animals, posing a danger to vulnerable groups such as the elderly and immunocompromised.
Researchers hope that next-generation Covid-19 vaccines could make the respiratory infection less of a threat by boosting mucosal immunity. These vaccines aim to shut down the virus before it makes us sick, ultimately preventing its spread.
One scientist, Emanuel Wyler, describes the nasal vaccine's approach as "bit like stationing firefighters underneath the smoke alarm in your house." The vaccine works by mimicking the natural process of infection and boosting immune defenses in the upper airways.
However, experts caution that more testing is needed before this vaccine can be widely used. Dr. Greg Poland from the Mayo Clinic notes that while the results are promising, there's still much to be done โ including repetition of the study in primates and humans.
In fact, there are already at least four nasal vaccines for Covid-19 in late-stage testing in people, according to the World Health Organization's vaccine tracker. These include those from Codagenix, which uses a live but weakened version of the virus similar to the German-developed vaccine.
While some experts see this approach as promising, others have concerns about its effectiveness and safety, particularly for vulnerable populations like those with compromised immunity.